Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 8, Issue 9, Pages 997-1008Publisher
EXPERT REVIEWS
DOI: 10.1586/ERI.10.90
Keywords
adjunctive; cerebral; human; malaria; Plasmodium falciparum; severe; treatment
Funding
- National Institute of Neurologic Disorders and Stroke [5R01-NS055349]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055349] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Severe malaria due to Plasmodium falciparum causes more than 800,000 deaths every year. Primary therapy with quinine or artesunate is generally effective in controlling P. falciparum parasitemia, but mortality from cerebral malaria and other forms of severe malaria remains unacceptably high. Long-term cognitive impairment is also common in children with cerebral malaria. Of the numerous adjunctive therapies for cerebral malaria and severe malaria studied over the past five decades, only one (albumin) was associated with a reduction in mortality. In this article, we review past and ongoing studies of adjunctive therapy, and examine the evidence of efficacy for newer therapies, including inhibitors of cytoadherence (e.g., levamisole), immune modulators (e.g., rosiglitazone), agents that increase nitric oxide levels (e.g., arginine) and neuroprotective agents (e.g., erythropoietin).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available